Big pharma has had teams and infrastructure in China for decades. Emerging biotech is being asked to build that capability almost overnight.
In the past two weeks:
A CEO shared that his board asked him to figure out how to run a clinical trial in China. He spent months speaking with hundreds of people, traveling back and forth, and attending dinners where navigating language gaps made it hard to assess who could actually execute.
A CBO is trying to figure out how to diligence potential Chinese out-licensing partners.
The scientific and operational capability in China is real. From here, knowing who can truly execute is the harder part.
10.1K views · 73 engagements
View on LinkedIn